Teleflex Incorporated (TFX) Earnings Call Transcript & Summary

April 28, 2022

New York Stock Exchange US Health Care Health Care Equipment and Supplies earnings 51 min

Earnings Call Speaker Segments

Lawrence Keusch

executive
#1

Hello everyone, and thank you for joining us for Teleflex Incorporated's earnings conference call covering the first quarter of 2022. You can find the press release and the slides that go with this call on our website, teleflex.com. Just a note that this call is being webcast on our site, and a replay will also be made available. For information about how to listen to that replay, please check this morning's press release. On the line with us today are Liam Kelly, our Chairman, President and Chief Executive Officer, along with Thomas Powell, our Executive Vice President and Chief Financial Officer. Liam and Tom are going to give some prepared remarks, and after that, we'll take your questions in the Q&A session. Before we get started, I want to remind everyone that certain matters we'll discuss during this conference call will include forward-looking statements about future events, as described in our slides; we want to caution you that these statements are indeed forward-looking by nature and are subject to risks and uncertainties, and actual events or results could differ materially. Among the factors that might cause actual results or events to differ materially are, but are not limited to, those referenced in today's press release, along with our filings with the SEC, including our Form 10-K, which you can access on our website. During this conference call, you'll hear management make statements about intra-quarter business performance. Management is offering this commentary to give the investment community additional insights concerning trends, and these disclosures might not occur in subsequent quarters; having said that, I'll now hand the call over to Liam for his remarks.

Liam Kelly

executive
#2

Thanks, Larry, and hello everybody. It's great to be with you this morning. In spite of a tough operating climate, Teleflex is still performing strongly. During Q1, our constant currency revenue rose 3.2% compared with the same period a year earlier. After accounting for the roughly 1% effect of having one fewer selling day this quarter versus last year's comparable period, plus the effect of shedding our 2021 respiratory business, underlying growth for the quarter came to 5.8% year-over-year, even with certain COVID-related interruptions in January and the early part of February. Adjusted EPS rose 0.3% from a year ago, reaching $2.88, which mirrors business growth partly offset by added inflation and spending on our growth drivers. As before, our solid quarterly results came from the company's mix of growth drivers, a wide range of medically necessary products and category leadership, partly offset by COVID-19 and the respiratory asset divestiture. Even though a spike in COVID infections caused disruption during the first half of the quarter, March came in better than we had expected. To be specific, January and early February saw a significant effect, caused by postponed procedures, patients' hesitancy and both patients and caregivers catching COVID, all of which hurt procedure volumes. Yet once COVID infections fell, we observed a clear rebound in our business as February came to a close. Within the quarter, our high growth portfolio—roughly 25% of 2021 revenues, comprising UroLift, MANTA, hemostatic products, EZ-IO, OnControl and PICCs—delivered well. If you set aside UroLift, which was expected to gain momentum as the year went on, the other products in that high growth portfolio rose by the low double-digits after adjusting for one fewer selling day this quarter; for 2022 we still anticipate mid-teens growth from our high growth portfolio as conditions return to normal and UroLift improves beyond its first quarter levels. Our durable core remains positioned to achieve 4% growth in 2022, consistent with what our guidance assumes. On the whole, we're happy with how we performed in Q1, notwithstanding COVID-related interruptions and year-over-year inflationary pressure from freight, raw materials and labor. I'm also glad to share that our pricing approach has built momentum early this year, and I have strong confidence that we will deliver our plan of 50 basis points and positive pricing in 2022; we keep assuming a more normalized operating environment as 2022 unfolds, given fewer COVID disruptions and more elective surgical procedures. Since we're still early in the year, we are holding our constant currency and adjusted earnings per share guidance for 2022. I want to thank the whole Teleflex team once more. The organization's resilience keeps holding strong. Even though pandemic disruptions have lasted longer than we expected, I think the Teleflex team is handling this extremely well. Our team members' commitment and effort remain evident across the entire company, as well as among our customers, patients, and communities. Building on that, let's take a closer look at the revenue results for our first quarter. I'll start by reviewing the revenues for our reportable segments in Q1. Unless stated otherwise, every growth rate mentioned is on a constant currency basis. In the first quarter, all four of our segments — Americas, EMEA, Asia, and OEM — proved resilient, with each region posting constant currency revenue growth compared with the prior year. Once again, the advantages of our diversified product portfolio continue to show in this difficult environment. Americas revenues came in at $378 million, reflecting 0.8% growth year-over-year. Within the quarter, surgical led the way as the largest growth driver, though this was partly offset by COVID-19's impact and one fewer selling day. If you set aside the selling day effect, the Americas region grew roughly 2.3% year-over-year. The respiratory divestiture created only a minimal headwind for Americas growth during the quarter. EMEA revenues reached $136.9 million, rising 3.4% year-over-year, with Interventional, Vascular Access, and Anesthesia products driving that increase. EMEA remained exposed to a COVID-19 headwind in early January, and afterward procedure volumes recovered as countries throughout the region kept reopening. Without the respiratory divestiture's impact, revenues climbed 7% year-over-year. Now on to Asia. Revenues totaled $69.2 million, up 12.5% year-over-year. China revenues grew at a robust double-digit rate, powered by gains in Vascular and Surgical. Meanwhile, Southeast Asia and Japan also added to the quarter's performance. Without the respiratory divestiture's impact, Asia revenues climbed 18.5% year-over-year. Let's now discuss our first quarter revenues by global product category. Matching what I said earlier about our reportable segments, the commentary on global product category growth for Q1 will likewise be on a constant currency basis and ordered by the size of our business units. Beginning with Vascular Access, revenue climbed 3.2% to $166.1 million. Our category leadership in central venous catheters and mid lines, together with our novel coated PICC portfolio, keeps positioning us for reliable growth. PICC growth matched internal expectations for the quarter. We anticipate that PICCs will outpace the market with double-digit growth for 2022 as we invest behind our differentiated portfolio. Shifting to Interventional, revenue was $96.9 million, up 2.3% year-over-year. We executed well in the quarter, with growth across our broad portfolio. We keep investing behind our interventional portfolio, which includes complex catheters and MANTA, our large bore closure device. MANTA revenues met expectations in the quarter, with usage continuing to grow both in the U.S. and in international markets. As a result, we remain on track for our 2022 revenue objectives. Now to Anesthesia, revenue was $86.9 million, up 5% year-over-year. LMA single use masks and aesthetic products, atomization and airway all contributed to growth in the first quarter, partly offset by lower sales of tracheostomy products. Sales from hemostatic products matched what we had anticipated for the quarter. Within Surgical, we brought in $89.7 million, which marks 14.4% growth compared with the same period last year. Looking at our biggest product lines, we keep seeing strong momentum in metal and polymer ligation clip sales, though that was partially offset by the timing of orders in our instrument business. Turning to Interventional Urology, revenue reached $74.9 million, up 2.2% versus a year ago and a bit ahead of what we had projected internally. As we anticipated, results for the quarter took a hit from the significant surge in COVID cases during January and February, which affected patients and also led to staffing shortages; even so, conditions in the operating environment improved sequentially as pandemic-related pressures started to subside. OEM revenue rose 9.2% from a year earlier, reaching $57.7 million. Our order book continues to be solid, as customers appreciate the breadth of our capabilities. We are well positioned with competitive strengths throughout our markets, including higher-growth opportunities in fin mold and advanced interventional microcatheters for neurovascular and other uses. Lastly, our other category — covering respiratory product sales excluded from the Medline divestiture, urology care, and manufacturing and supply transition agreement revenue tied to our respiratory divestiture — fell 11.7% year-over-year to $69.5 million.

Liam Kelly

executive
#3

That drop is tied to revenue we no longer have, because we divested the respiratory products, though manufacturing and supply transition agreement revenues gave us some offset. Our expectation hasn't changed: those manufacturing and supply transition agreement revenues should keep partially cushioning the hit to our revenue growth from the divested respiratory assets through the first half of 2022, and all MSA revenues got phased out at the end of 2023. That wraps up what I have to say about first quarter revenue performance. Now for some commercial updates, beginning with UroLift. We still see UroLift set up for accelerating growth in the second half of 2022 as pandemic headwinds ease over the course of the year and elective surgical procedures face fewer disruptions. So our 15% year-over-year growth outlook for the year is unchanged. UroLift stays differentiated from other outpatient BPH treatments, thanks to strong clinical results, studies demonstrating rapid symptom relief and recovery, no new sustained sexual dysfunction, and durable results. If you follow Teleflex, you know UroLift is being positioned for patients suffering from BPH who have failed drug therapy or aren't satisfied with it. Our DTC program continues to be a key part of our market building efforts and looks ready for another successful year, with internal metrics tracking at or above plan in the first quarter. As we've said before, we are laser focused on lifting UroLift utilization among existing users and boosting productivity from the roughly 900 surgeons trained during the pandemic. Our sales force is fully engaged in advancing the UroLift 2 rollout, and we anticipate conversion of the vast majority of our U.S. users by the end of 2022. Importantly, feedback from surgeons who have already converted to the new device has been very good. On top of that, UroLift 2 remains a key margin driver, and once the U.S. user base is fully converted, we stay positioned to deliver approximately 400 basis points of UroLift gross margin expansion. In our view, a tactical approach to bringing existing UroLift users back toward pre-pandemic procedure levels is the most effective way to improve growth in 2022. It's still early days, but we're encouraged by the improvement in growth we're seeing from existing UroLift users. Now an update on our international expansion strategy for UroLift: we launched UroLift in Japan on time, consistent with the April 1st implementation of reimbursement. Initial cases with key opinion leaders are now complete, and we are methodically ramping up volumes. Feedback from those first cases has been overwhelmingly positive, reflecting both the clinical benefits of the UroLift System and our field clinical capabilities. While we view 2022 as a building year for Japan, the contrary remains an important long-term opportunity for UroLift with a 2 billion TAM, and we're excited to bring this clinically beneficial treatment to those suffering from BPH. Our expectation remains that sales within that region will scale up much as they did in the United States, in a market roughly one-third the size. Looking ahead to the back half of 2022, we foresee updated reimbursement in France, and we're anticipating launch efforts across chosen areas of Italy and Spain. We continue to anticipate securing clearance for UroLift in China during 2023. Moving to the Vascular segment, we were recently granted a Sole Source Group Purchasing Agreement award alongside Vizient covering the provision of central venous access products. Under this group purchasing agreement, access is included to Teleflex's premier CVC portfolio featuring differentiated antimicrobial technology, plus the ErgoPack complete system that launched recently. This agreement takes effect in August and ought to drive additional revenue for Teleflex across the coming several years. Even so, the agreement's impact had already been factored into our annual guidance for 2022. On the subject of possible label expansion chances within the hemostatic product portfolio, as we stated before, we have finished enrolling patients in a 231 patient IDE study assessing how QuikClotControl+ Hemostatic devices perform for mild to moderate bleeding in cardiac procedures, measured against standard gauze. We continue to be on schedule with our regulatory milestones and recently submitted 510(K) for expanded use of QuikClotControl+; that brings my prepared remarks to a close. At this point, I'd like to hand the call over to Tom for a more detailed review of our first quarter financial results. Tom?

Thomas Powell

executive
#4

Thank you, Liam, and good morning. Since we already covered how the company's revenue performed, I'll start with margins. Gross and operating margins came down versus the same period a year ago in the first quarter, which is what we had expected. Adjusted gross margin for Q1 came to 58.4%, which is a decline of 100 basis points from the equivalent period last year. That year-over-year drop stemmed from added inflation in freight, raw materials and labor, with favorable pricing providing a partial offset. Inflation, as we had expected, contributed most to the fall in gross margin versus last year during Q1. Our 2022 guidance, as noted earlier, assumes a 70 basis point hit to gross margin from added inflation. For Q1, adjusted operating margin landed at 25.7%, a decline of 180 basis points year over year. Two factors drove that: a lower gross margin and deliberate spending on growth initiatives. Tighter cost control kept the drop from being larger. Net interest expense in Q1 totaled $10.2 million, compared with $16.1 million during the same quarter a year ago. The decrease reflects money saved by redeeming the 2026 senior notes ahead of schedule, plus the impact of paying down debt with funds from the respiratory divestiture and cash generated by operations. Our adjusted tax rate came in at 11.9% for Q1 of 2022, compared with 13.9% a year earlier. When you compare this year to last, the drop in our adjusted tax rate is mostly due to additional improvements we've made in the tax efficiency of our worldwide structure. That said, some costs from the new U.S. tax law's requirement to capitalize certain R&D expenses partially offset that benefit. Looking at the bottom line, adjusted EPS for Q1 came in at $2.88, essentially unchanged from a year ago. Now for a few balance sheet and cash flow points. Operating cash flow during the first quarter reached $62.1 million, down from $110.8 million in the same period last year. The main reason for the drop was negative working capital movements, which came from bigger bonus payouts during Q1 tied to stronger results in 2021 compared with 2020. Cash flow also took a hit because we built up inventory to back future expansion and to reduce exposure to possible supply chain interruptions. Turning to the balance sheet, our financial condition is still solid. We finished the first quarter with $466.7 million in cash, versus $445.1 million at the close of 2021. Net leverage stood at roughly 1.7 times at quarter's end, still comfortably under the 4.5 times covenant. Let's now turn to our 2022 guidance. We're holding to our forecast that constant currency revenue will rise 4% to 5.5% during 2022. On top of that, reported revenue growth for 2022 is still anticipated to land between 2.3% and 3.8%, which works out to a dollar range of $2.874 billion to $2.917 billion. If you set aside the year-over-year headwind tied to the respiratory divestiture, our underlying constant currency revenue growth remains projected at 5.5% to 7%. Turning to profits, we're reiterating our guidance for adjusted earnings per share, unchanged at $13.70 to $14.30 for 2022 — representing an increase of 2.8% to 7.3% versus the prior year. Inside that outlook, we continue to factor in pressures from the respiratory divestiture along with inflation, which together come to roughly $0.50 over the course of 2022. When you set aside the respiratory divestiture and the added inflation, earnings per share growth should come in at roughly 7% to 11%. That wraps up what I had prepared to say. At this point, I'll hand things back to Liam for some closing thoughts.

Liam Kelly

executive
#5

Thank you, Tom. To wrap up, I'd like to emphasize three main points from Q1 along with what we expect for 2022. To begin, because of our varied product lineup, Teleflex achieved constant currency growth of 3.2% during the first quarter, even with yet another surge of COVID. Once you account for one fewer selling day and the negative impact of the respiratory divestiture, growth in the underlying business came in near 6%. Next, we'll keep running the business efficiently and seek opportunities to reduce additional pressures stemming from inflation and supply chain issues. While currency movements are something we cannot influence, we maintain strong confidence that we can meet our 2022 financial guidance. Finally, we're still carrying out our long-range growth strategy. We'll keep making incremental investments in our high growth portfolio while generating reliable expansion within our durable core portfolio. We have the means available to push margins even higher, and our balance sheet remains strong, with leverage sitting at 1.7 times, which gives us substantial financial flexibility for our capital allocation priorities, M&A included; we stay confident about what lies ahead and about our capacity to keep fulfilling our promises to patients, clinicians, communities and shareholders; that wraps up my prepared comments; at this point, I'd like to hand the call back to the operator for the Q&A session.

Jayson Bedford

analyst
#6

Morning, and thank you for taking my questions, guys. Perhaps to kick things off — hey, you restated the UroLift guidance of 15% for this year. I was just curious whether the cadence has shifted at all regarding the gating between Q2 and the second half? Then, on a wider note, what do you see as the gating factor at present for wider adoption? Is COVID genuinely behind us? Are you still dealing with — running into some staffing issues that are — that are causing growth to slow?

Liam Kelly

executive
#7

Jayson, I appreciate the question. Well, to begin with, I'd tell you we feel quite confident about our UroLift guidance for the full year. I believe the year is unfolding much the way we anticipated on a year-to-date basis. January took a hit from COVID across the initial two months — or two weeks of February. Yet we still finished with positive growth, slightly better than what we had expected, thanks to the strength we witnessed heading into March. Our outlook hasn't shifted at all, Jayson; we continue to anticipate low-single digits for the first half, and we anticipate improvement in the second half that builds to 15% growth for the full year. That second-half acceleration stems really from the second part of your question; we'll have moved past COVID, we see patient confidence coming back, and we definitely see procedure volume beginning to return. In quarter one, I was traveling and I sat down with 32 urologists, Jayson; and it's difficult not to feel optimistic about a back-half recovery based on what those urologists told me; they recognized that urology procedures are starting to return. Patient confidence is starting to return. So I suppose I'll wrap up on your question by saying, yes, we feel really good about 15% in the back half of the year. And you're aware that when you head into Q3, Jayson, it's merely a matter of math. If you recall Q2 of last year, we posted $94 million — $92 million, and Q3 of last year came in at $83 million. So most of that growth simply arises from run rate as you move from Q2 into Q3. Then you'll notice in the back half, I think Q4, you typically see an uptick in Q4. And as people tap their deductibles, that drives it, plus you'd also anticipate existing doc utilization to rise as we see DTC begin to flow through too. So every one of the metrics tells us that 15% is solid, Jayson, and we feel quite confident about it.

Jayson Bedford

analyst
#8

Alright. That's extremely, extremely obvious. Appreciate it, Liam; and only as a brief additional question. Clearly this has been an unstable marketplace, private as well as public in this case, under 2 times levered relative to the stated goal of putting capital to work. So what I want to know is, has this situation affected any of your choices about allocating capital?

Liam Kelly

executive
#9

No, the marketplace hasn't. If anything I'm feeling positive, I'm feeling considerably better about the markets than I was a year ago. You're correct, our leverage has dropped now to 1.7 times. So to pursue M&A, what matters most is having firepower. We're pursuing assets, I can't say when we'll get efficient on both, but we have plenty of — we have lines out there, with highly appealing hooks attached; we're going to preserve our financial discipline, Jayson. And I believe the exuberant character of the IPO market that we witnessed in 2021 has cooled off; therefore we believe it's a favorable environment for Teleflex given the firepower we possess to keep pursuing M&A. Naturally, we'll keep funding R&D, we'll keep funding our restructuring programs too, but what we're chiefly focused on at this moment is out there hunting for a pleasant — a solid M&A possibility, scale tuck-in, dealer to direct and additionally late-stage technologies.

Cecilia Furlong

analyst
#10

Hi there, good morning, and thanks for giving me the chance to ask. Liam, I'd like to pick up where we left off regarding your short-term view, particularly how you see things playing out with the effort to address staffing shortages. Could you walk through the positives and negatives specifically for 2Q as we look at it, and then for UroLift too — what's the chance that staffing shortages affect that market in the near term, and then past 2Q as well?

Liam Kelly

executive
#11

Sure. What I'd say first, Cecilia, is that we reaffirmed our guidance for the full year, so that should signal how confident we are and where our numbers stand. On China, I'll begin there and then get to UroLift — regarding China, like we mentioned in our prepared remarks, Q1 delivered genuinely robust double-digit growth there, with APAC up 18.5% excluding the respiratory divestiture, and of course lockdowns are happening in Shanghai along with certain port closures. Typically we keep a couple of months of inventory in the channel. So provided the lockdowns don't turn into something drawn out and broad, my view is that Teleflex can handle this situation quite well. And to give everyone the baseline, China accounts for roughly 4% of our global revenues, and we don't make any products inside China. On the UroLift question and staffing shortages, once more, when I sat down with those 32 urologists, two points truly stood out to me from what they told me. First, every one of them has seen patients walk in because of our DTC. That's clearly a plus for us — it's making a difference out there. And the second point I took from them is that yes, they had been affected and are still being affected by staffing shortages, yet conditions are improving. They're witnessing a better environment — and keep in mind this was February, out on the road. So they were starting to notice improvement as they emerged from the far side of COVID, and they were confident about their ability to deal with their staffing charges. It's far more severe in the office than in the ASC, and that's what I observed in the office during those conversations too. So I still expect there will be somewhat of a staffing problem once you reach Q2. My sense is it improves as you move toward the latter part of the year, which is actually pretty favorable since I also expect patient confidence to strengthen as you progress through Q2, then Q3 and Q4.

Cecilia Furlong

analyst
#12

Much appreciated. And could I also ask a follow-up regarding MANTA, picking up from the money we put in during the back half of last year? What's your thinking on how that business unit will grow in 2022? Thanks again.

Liam Kelly

executive
#13

Thank you, Cecilia. Like we've been saying from the start of the year, we expect MANTA to expand by more than 50% this year, basically, thanks to that spend and a sharper emphasis on driving greater adoption. We now think we can train additional docs, and we also believe international growth, especially within EMEA, will be pretty strong. So our confidence remains. And as I mentioned during my prepared remarks, MANTA delivered a good, solid first quarter despite COVID's impact in January and early February.

Shagun Singh

analyst
#14

Much appreciated for the question. Liam and Tom, the outlook you just provided continues to indicate a wide range for EPS, and despite the Q1 beat it remains unchanged; so might you walk us through what is currently offsetting matters given that Q1 landed ahead — what assumptions apply at the top end as opposed to the bottom end. And given the extra strain from FX and inflation, would you say you're more comfortable at the top end or the bottom end? Then, for a second question, might you talk about FX? As I understand it, the euro spot rate incorporated in your initial guidance was 1.12, and at present it appears to be trading at 1.05; so per my math, that could represent a considerable headwind; so what is offsetting it? Thank you.

Thomas Powell

executive
#15

Well, to begin with, on the EPS front, we're quite pleased with the way the first quarter turned out despite the difficult COVID backdrop — constant currency revenue growth reached 5.8% after you account for the respiratory asset divestiture and one less shipping day. I'd also mention that expenses landed pretty much where we anticipated. Having said that, as you note, foreign exchange and interest rates have been rather volatile of late. So we'd rather allow ourselves another quarter to observe how things develop before making any adjustment to earnings. Regarding foreign exchange, our guidance came out at the beginning of the year, and it was set when the euro was at $1.12. Back then, we pointed out that this would translate into a 170 basis point headwind to revenue and a 20 basis point headwind to EPS. The rule of thumb we've shared previously — and naturally this may be offset, partially offset, or pushed further by other currencies as well — but where the euro is concerned, the rule of thumb is that every penny of movement works out to approximately a $0.05 full-year impact on earnings, or about $0.01 per quarter. Now that one quarter has passed, I'd estimate it at roughly $0.035 to $0.04 for every penny of euro movement. And again, currency fluctuations elsewhere in the world might partially offset that number. But I'd say that in considering the guidance we just gave and reaffirmed, we are factoring in what we observe in the inflationary environment, and the assumption there is that the inflationary conditions witnessed in the first quarter will largely continue for the remainder of the year. That is incorporated into our guidance.

Larry Biegelsen

analyst
#16

Hello, and thanks for fitting in my question. I just have a single one, Liam — you have an Analyst Meeting scheduled for next month. At a broad level, do you have any perspective on how you feel regarding that 6% to 7% LLP growth algorithm, and the fact that street models presently assume roughly 100 basis points of leverage each year following 2022? Whatever insight you could offer before we get to that meeting would be welcome. Thank you very much.

Liam Kelly

executive
#17

Sure, Larry, I appreciate the question a lot. Look, we are genuinely excited about connecting with the investment community in late May. What I believe we will be sharing is top line growth that is durable and sustainable. I would rather not attach a figure to it at this moment, but if you can hold on for a few more weeks, Larry, we will be revealing that. We intend to demonstrate margin expansion inside Teleflex. Restructuring programs remain underway for us. We also still have mix working to our advantage. Naturally, we will talk about cash flow generation and capital deployment. As I mentioned before, M&A, R&D, and a portion of the restructuring programs form the primary emphasis of our capital deployment. And clearly, you will observe that we keep concentrating on ESG. So those, I believe, are the broad themes we will cover with the investment community. And clearly we will put investment behind our high growth portfolio and share our expectations regarding that side of our business too. That 25% of our portfolio strikes us as very exciting. UroLift is obviously part of it, yet Teleflex involves far more than UroLift, and we want the investment community to recognize that. MANTA is very exciting, our hemostatic portfolio is very exciting, our Intraosseous portfolio along with our PICC portfolio, all possessed genuinely strong growth drivers. And in fact, from a margin standpoint, UroLift sits in the middle of the pack. So there is broad appeal across Teleflex, and that is another thing we wish to convey.

Larry Biegelsen

analyst
#18

OK, I really appreciate you answering my question.

Liam Kelly

executive
#19

Thank you, Larry.

Analyst

analyst
#20

Hey everyone, good morning. Drew here, filling in for Matt, and I appreciate you taking the questions. Perhaps you could give us some color on the very near term for UroLift — what are you actually observing on the ground when it comes to volume? My understanding is the Street has volume growing mid single digits in Q2. Does that match what you're currently seeing? And then — have you noticed any significant shifts in site of care during this year so far?

Liam Kelly

executive
#21

Could you say that last part of your question again? Significant shifts —

Analyst

analyst
#22

Regarding where procedures are performed —

Liam Kelly

executive
#23

Yes, many thanks; so essentially what we observed, as I mentioned before during my commentary, is that for UroLift we still anticipate low single-digit expansion during the first half, followed by a pickup in the second half, and we have strong conviction about 15% for the entire year. And things truly are unfolding the way we expected as a business. Clearly, January and early February COVID effects hit Q1. What we witnessed in March gave us encouragement. Recovery's early signs did appear in March. Additionally, the approach we've put in place around concentrating on current users and providing training to those 900 physicians who joined us amid the pandemic is likewise demonstrating initial positive signals, and what we're observing there gives us encouragement. We're boosting physician usage of UL 2 and ATZ. And clearly our DTC initiative is strengthening our assurance regarding UroLift's expansion. I'm genuinely happy to share that we've observed zero movement in where care is delivered and we don't foresee any movement in where care is delivered. Our new pricing approach has been accepted by the overwhelming majority of our office based urologists, and it is now in place and being fully rolled out. So no movement in where care is delivered, and none is expected for the rest of the year. And once more I'll repeat that we feel good about 15%.

Analyst

analyst
#24

All right, that's quite useful. Then a brief additional question regarding what you said about favorable pricing: how should we view that 50 bps of price — the positive price — relative to the cost pressures you're encountering? And when — depending on when you believe those cost pressures might ease — could there be an opportunity to raise that price further should those pressures prove more stubborn? Thanks.

Liam Kelly

executive
#25

A wise saying from my dad was that half the battle is won by starting well. Our pricing and the introduction of our pricing have begun well, and that gives me a lot of encouragement. As for what you asked about its effect on inflation, we anticipate 50 basis points of favorable pricing alongside 70 basis points of inflation, and our forecast already accounts for that. There is, I believe — Teleflex has consistently been an organization capable of achieving favorable pricing. And should inflation worsen, I genuinely think we have a degree of room to raise our prices going forward.

Matthew Mishan

analyst
#26

Morning, and I appreciate you taking the questions. Liam, would you mind walking us through a few of the things happening in the Interventional segment, and what sort of growth we ought to have in mind there for 2022?

Liam Kelly

executive
#27

Sure thing, Matt, and thanks for asking. The way we see it, our guidance from the start of the year hasn't shifted at all. With solid execution, we continue to anticipate high single-digits, low double-digits of growth from our Interventional portfolio. The first quarter, I'd say, landed just where we thought it would. January and early February brought some COVID-related pressure, which is to be expected, yet the bounce-back for interventional access looks pretty promising. Speaking more generally, my sense is that hospitals are handling the climb out of the far side of COVID better than ASCs and offices are, and that pattern shows up everywhere we look. So we feel quite confident about where that business is heading, and equally confident about where MANTA and the remaining portfolio are heading. Thus, high-single, low-double digits, provided execution is solid — that's my expectation for the year.

Matthew Mishan

analyst
#28

All right, great. So regarding Anesthesia, could you discuss Z-Medica compared with the rest of the Anesthesia portfolio and how it performed during the quarter?

Liam Kelly

executive
#29

Sure, as I mentioned during our prepared remarks, Z-Medica matched exactly what we had anticipated; we continue to anticipate that the Z-Medica portfolio, the hemostatic portfolio, will expand at a high-single to low double-digit rate assuming solid execution. So once again very pleased with the output from that hemostatic portfolio. And Matt, you could observe it in the figures. It has been some time since the Anesthesia portfolio recorded a 5% growth figure on an organic basis. So I believe we're fairly encouraged by that result in the first quarter.

Richard Newitter

analyst
#30

Pardon me. Hello, and I appreciate you allowing me to ask.

Liam Kelly

executive
#31

Good to have you with us again, Rich.

Richard Newitter

analyst
#32

Yeah, I hear you, thanks. Appreciate it. Being here again is wonderful. Many thanks, Liam. Perhaps I'll begin with UroLift — honestly, this has been quite an odd year when you look at it through the lens of growth rate. Clearly, the first half understates growth because of comps and COVID, and in the second half, like you mentioned, mathematically speaking it works out the same way to arrive at your guidance going from 15% to well above 20%. So I do recognize that 15% represents this year's growth in the growth rate outlook; but Liam, could you perhaps assist us in reasoning about what the proper normalized growth rate should be once we've sort of emerged past recovery and lapped all these various factors, hopefully? For the U.S. UroLift business right now, is 15% the correct frame of reference?

Liam Kelly

executive
#33

The way I see it, Rich, is that we have strong confidence in delivering 15% growth this year. And this year, the U.S. is what matters. You'll get a modest amount from overseas, with Japan ramping up somewhat this year. A little bit from Brazil, Italy and Spain, plus France, will show up in the second half. Then next year China will receive registration and we'll enter that market. And how I view it is we'll wrap up this year. We think we'll achieve 15% growth, and ideally we'll be past COVID and it will be behind us. Moving into the next year, you'll face an easier comp in the U.S. in that first year, and after that you ought to see contributions starting to scale up in international markets. And Rich, having you back is terrific, but if you could just hang tight for a couple more weeks, I'll share what UroLift will deliver across the coming three years at the Analyst Day when we're all together in New York.

Richard Newitter

analyst
#34

Great. I'm eager for that, Liam; and perhaps just one additional question. I may have overlooked it before, but your surgical results during this quarter, they landed considerably higher than what we had anticipated, correct? What exactly was behind that once more, and the 14% constant currency figure? Can that be maintained, or was there something included that we ought to be considering? And if you could as well just address 2Q? Any outlook or detail you can provide to help with modeling for the upcoming quarter regarding revenue and earnings? Thank you, Liam.

Liam Kelly

executive
#35

Sure, Rich, we kicked off the year anticipating our Surgical business would see low-single digit growth. Q1 finished a bit beyond what we had expected, and that was truly fueled by robust expansion in APAC and the U.S. as procedures keep recovering. Plus we observed some pricing advantage. This is among the segments where we consistently begin to apply pricing. We continue to anticipate lower single digits across the entire year, though perhaps solid execution and, once more, returning to what I mentioned before regarding pricing, if we can maintain it somewhat better across the rest of the year, we might reach the mid single-digits through strong execution in our Surgical business, which would represent a genuinely strong result for that business as a whole. So, once more, a solid beginning is half the battle, as my father puts it, and Surgical certainly had a solid beginning, yet we continue to anticipate low singles, maybe reaching mid with strong execution as we move through the year. And on a full-year basis, once more as I stated before, we feel truly confident about our — the widespread recovery, and we feel truly confident about our full-year guidance, and Surgical is no exception compared to the whole of Teleflex.

Mike Matson

analyst
#36

Yeah, appreciate you taking my questions. I suppose I'll pose another one regarding UroLift. So you guys have increased the DTC advertising. There appears to be somewhat of a puzzle here, since the timing of when — my thinking is that when you sort of increased that was aligned with many of these COVID effects and a deceleration in growth. And I get what's going on there and the sensitivity to infection rates and such; but I suppose what makes you confident that the DTC ads are truly showing they work and that you're receiving a sufficient return on the investment?

Liam Kelly

executive
#37

Well, clearly we track how effective our DTC campaign is. At the close of last year, we know that the — what we anticipated at the start of the year was to achieve 150% the number of impressions. We actually finished at nearly 200% across every one of the metrics, we examine the number of impressions, we examine how patients respond, we track the total estimated appointments and procedures. And we know from all of that, Mike, that this represents a good return on our investment. From anecdotes, when I was out with those 32 urologists during the first quarter, each of them had brought up that patients had come in and asked them about UroLift as a direct consequence of the DTC campaign. So from anecdotes and from measurement, we know that it is working. And we are seeing — and we do see the worth of priming the pump so as to place patients in the care of urologists. In full transparency, Mike, we don't care when the procedure gets done. As long as we are driving these patients to our urologist and the vast majority of urologist that are champions, only offer UroLift. So therefore it's very focused. That's the one thing I will say about our DTC, it is very focused on docs put patients arriving with doctors that use UroLift almost exclusively.

Mike Matson

analyst
#38

All right, understood. Then I just wanted to ask about the consensus for Q2 — I didn't really catch any commentary on where we ought to be modeling. I believe — I realize you don't provide quarterly guidance, but you do face a somewhat tougher comp in Q2. Are you comfortable with the top and bottom line consensus estimates for that — for Q2?

Liam Kelly

executive
#39

Yes, Mike, that's correct. Quarterly guidance isn't something we provide, but our yearly guidance has been reaffirmed; and I suppose I'll leave it there, that's — on all lines, we feel really confident about our yearly guidance.

Lawrence Keusch

executive
#40

Appreciate that, Elliot. And thanks as well to all of you who were with us on this morning's call. That brings the Teleflex Incorporated first quarter 2022 earnings conference call to a close.

Operator

operator
#41

Our conference call for today is now concluded. Thank you all for your participation.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Teleflex Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Teleflex Incorporated earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Teleflex Incorporated or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.